Breaking News Instant updates and real-time market news.

TEVA

Teva

$10.72

0.485 (4.74%)

, ITCI

Intra-Cellular

$9.22

-0.76 (-7.62%)

07:30
11/26/19
11/26
07:30
11/26/19
07:30

Unusual put flow in option market yesterday

Notable put activity was cited Monday in Teva (TEVA) and Intra Cellular Therapies (ITCI).

TEVA

Teva

$10.72

0.485 (4.74%)

ITCI

Intra-Cellular

$9.22

-0.76 (-7.62%)

  • 07

    Dec

  • 27

    Dec

TEVA Teva
$10.72

0.485 (4.74%)

11/12/19
JPMS
11/12/19
UPGRADE
Target $8
JPMS
Neutral
JPMorgan upgrades Teva to Neutral on stabilizing fundamentals
JPMorgan analyst Christopher Schott upgraded Teva Pharmaceuticals to Neutral from Underweight with an unchanged price target of $8. The analyst, who remains "fairly bearish" on the company's longer term setup, cites valuation for the upgrade with the stock down 55% year-to-date. Further, Teva's near-to-mid-term fundamentals are stabilizing, unlike some of its peers, Schott tells investors in a research note. As such, the analyst sees a "decidedly less-negative" setup today than several months ago.
11/12/19
11/12/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Argo Group (ARGO) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Christopher Campbell saying he believes the company's "sizable" Q4 International reserve charge will restore balance sheet confidence and that new CEO Kevin Rehnberg's U.S. Operations outperformance can be replicated in its International segment. 2. Live Nation (LYV) upgraded to Outperform from In Line at Evercore ISI with analyst David Joyce saying he believes Live Nation shares have "pulled back needlessly" following its Q3 earnings results, and recommended taking advantage of the pullback. 3. Rent-A-Center (RCII) upgraded to Buy from Hold at Stifel with analyst John Baugh saying the recent pullback in the shares creates an attractive entry point. 4. Crowdstrike (CRWD) upgraded to Neutral from Sell at Goldman Sachs with analyst Heather Bellini she sees a more balanced risk/reward with the stock down 23% since her October 11 downgrade to Sell. 5. Teva (TEVA) upgraded to Neutral from Underweight at JPMorgan with analyst Christopher Schott citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/18/19
OPCO
11/18/19
NO CHANGE
Target $12
OPCO
Outperform
Teva may be positioned to sustain U.S. generic revenue base, says Oppenheimer
Oppenheimer analyst Esther Rajavelu reviewed Teva's U.S. generic trends, saying that based on her firm's analysis, compared to 2017, GtN discounts may have narrowed during 2019, a higher proportion of Teva's current portfolio competes with fewer manufacturers, and more 2019 launches are in markets with less than or equal to 2 competitors. Based on these metrics, Rajavelu says Teva may be better positioned to sustain its U.S. generic revenue base. She keeps an Outperform rating and $12 price target on the shares.
11/20/19
JEFF
11/20/19
NO CHANGE
Target $9
JEFF
Hold
Teva 'offered little' on progress toward opioids settlement, says Jefferies
Jefferies analyst David Steinberg said Teva CEO Kare Schultz has "largely delivered" on stabilizing Teva's financials over the past two years on the job, but opioid litigation has overwhelmed the fundamentals lately. After hosting investor meetings at the company's headquarters in Israel, Steinberg said Teva "offered little in the way of tangible progress" toward getting its proposed opioid settlement approved by all the relevant parties. Steinberg, who notes that there are still 46 state attorneys general that need to opt in, said he believes that "seems uncertain" to happen. Given the opioid litigation is "clouding an already uncertain future," Steinberg keeps a Hold rating and $9 price target on Teva shares, though he added that management believes that the market is just about at the price stabilization phase of the generic drug pricing cycle.
ITCI Intra-Cellular
$9.22

-0.76 (-7.62%)

09/10/19
CANT
09/10/19
NO CHANGE
Target $27
CANT
Overweight
Intra-Cellular data turnaround time bodes well for PDUFA, says Cantor Fitzgerald
After Intra-Cellular Therapies announced it has provided the additional non-clinical toxicology data that the FDA requested, Cantor Fitzgerald analyst Charles Duncan says the "rapid" turnaround bodes well for the December 27 action date. Further, the analyst believes the FDA's current plans to not hold a panel meeting reflects the submission of a "robust" new drug application data package and lack of panel-worthy discussion points. He views view the second half of 2019 and early 2020 as "transformational" for Intra-Cellular and keeps an Overweight rating on the shares with a $27 price target.
09/10/19
LEER
09/10/19
NO CHANGE
LEER
Outperform
SVB Leerink says no AdCom 'probably good news' for Intra-Cellular
SVB Leerink analyst Marc Goodman reiterated an Outperform rating on Intra-Cellular after the FDA said it does not have plans to schedule an Advisory Committee, or AdCom, meeting in connection with its review of the company's New Drug Application for lumateperone for the treatment of schizophrenia. In a research note to investors, Goodman says that while he is "surprised" at the FDA's move, he notes that the FDA "has not been doing AdComs like they used to, and this product may fit into that new paradigm," and believes no AdCom is "probably good news." Goodman also notes that some investors have expressed concern with the efficacy data because of prior failed studies for Luma, but feels the FDA understands that this is a part of drug development in the category.
09/10/19
JPMS
09/10/19
NO CHANGE
Target $20
JPMS
Overweight
Intra-Cellular slide surprising following lumateperone update, says JPMorgan
JPMorgan analyst Jessica Fye said she is surprised that shares of Intra-Cellular are lower following the announcement that the FDA does not plan to schedule an Advisory Committee meeting to discuss lumateperone for schizophrenia. She thinks the base-case interpretation of the ad com update is positive, as it potentially is a sign of the FDA's comfort with lumateperone's risk/benefit and suggests the agency is comfortable evaluating the drug without outside feedback. The analyst, who added that management characterized their FDA dialogue as "very constructive" and said that they feel positive about the ad com update, is incrementally positive on the likelihood of approval following the update and keeps an Overweight rating on Intra-Cellular shares.
09/10/19
JMPS
09/10/19
NO CHANGE
Target $21
JMPS
Outperform
JMP Securities sees 'successful' review of Intra-Cellular lumateperone NDA
JMP Securities analyst Jason Butler reiterated an Outperform rating and $21 price target on Intra-Cellular following the announcement that the FDA does not plan to schedule an Advisory Committee meeting to discuss lumateperone for schizophrenia. In a research note to investors, Butler says he remains confident that the company has adequately addressed the FDA's questions and maintains his expectation for a "successful" NDA review and approval of lumateperone by the PDUFA date.

TODAY'S FREE FLY STORIES

HSIC

Henry Schein

$68.33

-0.35 (-0.51%)

08:57
12/11/19
12/11
08:57
12/11/19
08:57
Conference/Events
Henry Schein management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CRL

Charles River

$146.36

1.59 (1.10%)

, PRAH

PRA Health

$107.41

0.34 (0.32%)

08:56
12/11/19
12/11
08:56
12/11/19
08:56
Conference/Events
Jefferies to hold a bus tour »

North Carolina Healthcare…

CRL

Charles River

$146.36

1.59 (1.10%)

PRAH

PRA Health

$107.41

0.34 (0.32%)

PRXL

Acquired by Pamplona Capital 9/17

$0.00

(0.00%)

SYNH

Syneos Health

$56.21

0.87 (1.57%)

WST

West Pharmaceutical

$145.47

0.75 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHR

Danaher

$148.88

1.37 (0.93%)

, ARQL

ArQule

$19.95

0.245 (1.24%)

08:55
12/11/19
12/11
08:55
12/11/19
08:55
Options
Notable open interest changes for December 11th »

Tuesday's total…

DHR

Danaher

$148.88

1.37 (0.93%)

ARQL

ArQule

$19.95

0.245 (1.24%)

T

AT&T

$38.07

0.025 (0.07%)

TSLA

Tesla

$348.82

9.35 (2.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 07

    Jan

  • 29

    Jan

08:55
12/11/19
12/11
08:55
12/11/19
08:55
General news
Treasury Action: yields remain modestly richer »

Treasury Action: yields…

ACB

Aurora Cannabis

$2.52

-0.095 (-3.63%)

, CRON

Cronos Group

$6.84

-0.12 (-1.73%)

08:54
12/11/19
12/11
08:54
12/11/19
08:54
Conference/Events
MJBizDaily to hold a conference »

Marijuana Business…

ACB

Aurora Cannabis

$2.52

-0.095 (-3.63%)

CRON

Cronos Group

$6.84

-0.12 (-1.73%)

NFX

Newfield Exploration

$0.00

(0.00%)

CGC

Canopy Growth

$20.09

-1.17 (-5.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

ASPU

Aspen Group

$7.00

0.02 (0.29%)

08:52
12/11/19
12/11
08:52
12/11/19
08:52
Recommendations
Aspen Group analyst commentary  »

Aspen Group business…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 30

    Dec

LYG

Lloyds Banking

$3.20

-0.04 (-1.24%)

08:52
12/11/19
12/11
08:52
12/11/19
08:52
Conference/Events
JMP Securities to hold a field trip »

Lloyd's of London…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

NKE

Nike

$97.01

0.38 (0.39%)

08:51
12/11/19
12/11
08:51
12/11/19
08:51
Recommendations
Nike analyst commentary  »

Nike 'margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

CCBG

Capital City Bank

$29.30

0.23 (0.79%)

08:51
12/11/19
12/11
08:51
12/11/19
08:51
Hot Stocks
Capital City Bank to acquire 51% of BrandMortgage, terms not disclosed »

Capital City Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIOL

Biolase

$0.52

-0.0256 (-4.68%)

, RESN

Resonant

$1.83

-0.15 (-7.58%)

08:50
12/11/19
12/11
08:50
12/11/19
08:50
Conference/Events
LD Micro to hold a conference »

LD Micro Main Event will…

BIOL

Biolase

$0.52

-0.0256 (-4.68%)

RESN

Resonant

$1.83

-0.15 (-7.58%)

PSTV

Plus Therapeutics

$2.11

-0.06 (-2.76%)

HRTG

Heritage Insurance

$13.33

0.08 (0.60%)

ECOR

electroCore

$1.56

-0.2 (-11.36%)

GLOW

Glowpoint

$1.22

(0.00%)

THMO

ThermoGenesis

$2.96

0.11 (3.86%)

ALOT

AstroNova

$14.04

-0.08 (-0.57%)

ASPU

Aspen Group

$7.00

0.02 (0.29%)

SHSP

SharpSpring

$10.15

-0.37 (-3.52%)

NSSC

Napco Security

$30.00

-1.25 (-4.00%)

RCON

Recon Technology

$0.74

0.0263 (3.69%)

GIGA

Giga-tronics

$0.00

(0.00%)

VTSI

VirTra

$3.75

-0.045 (-1.19%)

ZDGE

Zedge, Inc.

$1.62

-0.13 (-7.43%)

CLXT

Calyxt

$5.53

-0.01 (-0.18%)

CPST

Capstone Turbine

$3.31

-0.255 (-7.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 19

    Dec

  • 30

    Dec

  • 26

    Feb

GHM

Graham

$21.99

0.13 (0.59%)

08:50
12/11/19
12/11
08:50
12/11/19
08:50
Conference/Events
Graham management to meet with Maxim »

Meetings to be held in St…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 13

    Dec

AZO

AutoZone

$1,250.39

79.085 (6.75%)

08:50
12/11/19
12/11
08:50
12/11/19
08:50
Recommendations
AutoZone analyst commentary  »

AutoZone quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 18

    Dec

08:50
12/11/19
12/11
08:50
12/11/19
08:50
General news
FX Action: The dollar »

FX Action: The dollar…

CFB

CrossFirst Bancshares

$14.24

0.545 (3.98%)

08:49
12/11/19
12/11
08:49
12/11/19
08:49
Initiation
CrossFirst Bancshares initiated  »

CrossFirst Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OLN

Olin

$17.16

-0.24 (-1.38%)

08:46
12/11/19
12/11
08:46
12/11/19
08:46
Hot Stocks
Olin shutting down two facilities in Freeport, Texas »

Olin plans to permanently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSLR

First Solar

$52.45

0.06 (0.11%)

, SEDG

SolarEdge

$81.46

-1.37 (-1.65%)

08:46
12/11/19
12/11
08:46
12/11/19
08:46
Recommendations
First Solar, SolarEdge, Sunnova Energy, Bloom Energy, Enphase Energy, Hannon Armstrong, TPI Composites analyst commentary  »

JPMorgan still…

FSLR

First Solar

$52.45

0.06 (0.11%)

SEDG

SolarEdge

$81.46

-1.37 (-1.65%)

NOVA

Sunnova Energy

$9.55

-0.08 (-0.83%)

BE

Bloom Energy

$5.19

-0.145 (-2.72%)

ENPH

Enphase Energy

$24.02

-0.01 (-0.04%)

HASI

Hannon Armstrong

$29.74

-0.04 (-0.13%)

TPIC

TPI Composites

$16.50

-0.45 (-2.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

GDS

GDS Holdings

$48.10

0.94 (1.99%)

08:46
12/11/19
12/11
08:46
12/11/19
08:46
Conference/Events
GDS Holdings management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NEPT

Neptune Wellness

$2.74

-0.04 (-1.44%)

, PAYS

Paysign

$10.32

-0.08 (-0.77%)

08:45
12/11/19
12/11
08:45
12/11/19
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

NEPT

Neptune Wellness

$2.74

-0.04 (-1.44%)

PAYS

Paysign

$10.32

-0.08 (-0.77%)

GME

GameStop

$6.50

0.18 (2.85%)

DDOG

Datadog

$34.76

-0.42 (-1.19%)

AKBA

Akebia

$6.40

0.46 (7.74%)

MED

Medifast

$89.27

0.315 (0.35%)

GOOS

Canada Goose

$38.79

0.065 (0.17%)

APHA

Aphria

$4.95

-0.13 (-2.56%)

CRON

Cronos Group

$6.84

-0.12 (-1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

08:45
12/11/19
12/11
08:45
12/11/19
08:45
General news
U.S. November CPI rose 0.3%, with the core up 0.2% »

U.S. November CPI rose…

IAC

IAC

$215.67

0.38 (0.18%)

, AMD

AMD

$39.44

0.53 (1.36%)

08:44
12/11/19
12/11
08:44
12/11/19
08:44
Conference/Events
UBS to hold a conference »

Global TMT Conference…

IAC

IAC

$215.67

0.38 (0.18%)

AMD

AMD

$39.44

0.53 (1.36%)

DOCU

DocuSign

$72.81

-2.66 (-3.52%)

CMCSA

Comcast

$42.77

-1.11 (-2.53%)

MDCA

MDC Partners

$2.58

(0.00%)

VRNS

Varonis

$75.13

-0.88 (-1.16%)

MTZ

MasTec

$60.85

-1.19 (-1.92%)

SWKS

Skyworks

$104.40

1.23 (1.19%)

DESP

Despegar.com

$12.53

-0.075 (-0.60%)

LITE

Lumentum

$68.90

-0.73 (-1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 16

    Dec

  • 17

    Dec

AZO

AutoZone

$1,250.39

79.085 (6.75%)

08:44
12/11/19
12/11
08:44
12/11/19
08:44
Recommendations
AutoZone analyst commentary  »

AutoZone price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 18

    Dec

GE

General Electric

$11.00

0.01 (0.09%)

08:43
12/11/19
12/11
08:43
12/11/19
08:43
Hot Stocks
General Electric, Agilyx announce collaboration in artificial intelligence »

Agilyx announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 29

    Jan

CPST

Capstone Turbine

$3.31

-0.255 (-7.16%)

08:43
12/11/19
12/11
08:43
12/11/19
08:43
Hot Stocks
Capstone Turbine announces nine-year FPP contract with Distributed Generation »

Capstone Turbine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ES

Eversource

$80.98

0.24 (0.30%)

08:42
12/11/19
12/11
08:42
12/11/19
08:42
Initiation
Eversource initiated  »

Eversource initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

FVRR

Fiverr

$21.54

1.28 (6.32%)

08:42
12/11/19
12/11
08:42
12/11/19
08:42
Conference/Events
Fiverr management to meet with JMP Securities »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.